Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT 22: Cisplatin + pemetrexed vs carboplatin + paclitaxel + bevacizumab in KRAS-mutated NSCLC
2015-003121-34Phase 3Active
- Sponsor
- NVALT
- Start
- Mar 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing cisplatin + pemetrexed with carboplatin + paclitaxel + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Mar 2016; status: active.
02
Drugs
cisplatinpemetrexedcarboplatinpaclitaxelbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-003121-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003121-34.